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Abstract
Background: Previous studies have suggested that the association between APOE ɛ 4 and dementia is moderated by physical activity (PA), 
but the results remain inconclusive and longitudinal data on cognitive decline are missing. In this study, we examine whether there is a gene–
environment interaction between APOE and PA on cognitive decline in older adults using 9-year follow-up data of three cohort studies.
Methods: We followed 7,176 participants from three longitudinal cohort studies: Longitudinal Aging Study Amsterdam (LASA), InCHIANTI, 
and Rotterdam Study for 9 years. PA was assessed with self-reported questionnaires and was categorized in low, moderate, and high PA. Cognitive 
function was assessed with the Mini-Mental State Examination (MMSE) and cognitive decline was defined as a decrease of three points or more on 
the MMSE during 3 years follow-up. We fitted logistic regression models using generalized estimating equations adjusting for age, sex, education, 
depressive symptoms, and number of chronic disease. Interaction between APOE and PA was tested on multiplicative and additive scale.
Results: Cohorts were similar in most aspects but InCHIANTI participants were on average older and had lower education. APOE ɛ 4 
carriers had higher odds of cognitive decline (odds ratio [OR] = 1.46, 95% confidence interval [CI]: 1.29–1.64) while PA was not significantly 
associated with cognitive decline overall (moderate PA: OR = 0.87, 0.67–1.13; high PA: OR = 0.71, 0.36–1.40). There was no evidence for an 
interaction effect between PA and APOE ɛ 4 in cognitive decline in older adults (APOE × moderate PA: p = .83; APOE × high PA: p = .90).
Conclusions: Previous claims of a gene–environment interaction between APOE ɛ 4 and PA in cognitive decline are not supported by our results.
Keywords:  Gene–environment interaction, Longitudinal Aging Study Amsterdam, InCHIANTI, Rotterdam Study
Dementia is an increasing public health problem due to the increased 
life expectancy and the aging population (1,2). It has a complex gen-
etic architecture and is largely influenced by lifestyle factors. In add-
ition to dementia, there is an increasing burden of cognitive decline 
in the population.
Apolipoprotein E ε 4 (APOE ε 4) is the main genetic risk factor 
for dementia (3–5). Furthermore, the ε 4 isoform of the lipoprotein is 
directly involved in the biological pathway of dementia and cognitive 
decline. It reduces the clearance of soluble amyloid beta (Aβ) from the 
brain and increases its deposition in senile plaques (6,7). In addition, 
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several studies have shown that APOE ε 4 carriers have more Aβ de-
position in senile plaques in the brain compared to noncarriers (8,9).
Along with genetic factors, different lifestyle factors affect de-
mentia and cognitive function in older individuals. Previous studies 
suggest that physical activity (PA) (10–12) has a positive effect 
on cognitive function. The exact mechanisms remain unknown 
but several theories are proposed such as enhancing cerebral per-
fusion, effects of PA on angiogenesis, neurogenesis, reduction of 
neuroinflammation, and reduction of Aβ deposition (13,14).
In the last years, a gene–environment interaction (GxE) be-
tween APOE and PA in Alzheimer’s disease (AD) has been suggested 
(15,16). A recent review by Bos and colleagues emphasizes the im-
portance of identifying modifiable lifestyle factors for high-risk 
APOE ε 4 carriers (17). The underlying biological mechanisms of 
this interaction are not completely understood but it is hypothesized 
that APOE ɛ 4 carriers are more vulnerable to nonfavorable lifestyle 
factors compared to noncarriers. The study of Head and colleagues 
(14) showed that PA moderates the effect of APOE genotype on Aβ 
deposition with extra benefit in APOE ɛ 4 carriers.
However, current literature on APOE ε 4 by PA interaction is in-
conclusive and mainly focused on AD. Some studies suggest a stronger 
protective effect of PA on dementia in APOE ε 4 carriers compared 
to noncarriers (18,19). Conversely, findings from Cardiovascular 
Health Cognition Study and Canadian Study of Health and Aging 
analyzing the effect of PA on dementia suggest a stronger protective 
effect of PA in APOE ε 4 noncarriers compared to carriers (20,21).
Here, we aimed to explore whether PA might moderate the effect 
of APOE genotype on cognitive decline. Thus, we tested whether the 
GxE interaction between APOE genotype and PA was associated 
with cognitive decline in the general population of older individuals, 
using data from three prospective population-based cohort studies 
with longitudinal measurements.
Methods
Study Participants
This study includes data from three ongoing prospective co-
hort studies: the Longitudinal Aging Study Amsterdam (LASA), 
Invecchiare in Chianti (InCHIANTI), and Rotterdam Study (RS). 
A  description of each study can be found in the Supplementary 
Material. The main analysis includes participants of Caucasian eth-
nicity, aged 55 years and older who underwent repeated cognitive as-
sessment with the Mini-Mental State Examination (MMSE), and had 
a baseline MMSE score ≥18. Participants who were bedridden or in 
a wheelchair were excluded from the analysis. In total, 7,176 parti-
cipants with 18,489 observations during 9-year follow-up were ana-
lyzed; respectively 1,736 participants with 4,255 observations from 
LASA, 843 participants with 2,132 observations from InCHIANTI 
study, and 4,597 participants with 12,102 observations from RS 
(Supplementary Figure 1). Mean follow-up period between two 
consecutive measurements was 3 years for LASA and InCHIANTI 
and 4 years for RS (Supplementary Table 1). Informed consent was 
obtained from all participants in each study and all studies have been 
approved by the respective Medical Ethics Committees.
Assessment of APOE
In LASA, both phenotyping and genotyping of APOE were available. 
Phenotyping was performed at the Immunochemistry Laboratory 
of VUmc, Amsterdam (22). Genotyping was performed using the 
Axiom-NL array from Affymetrix (Avera Institute for Human 
Genetics, South Dakota) or the Infinium Global Screening Array 
from Illumina (Genetic Laboratory, Erasmus MC, Rotterdam, the 
Netherlands). APOE could be inferred from two single-nucleotide 
polymorphisms (SNPs), rs429358 and rs7412. A  comparison be-
tween phenotyping and genotyping status of APOE showed 96.9% 
agreement between the two methods. Because more participants 
had phenotyping data (N  =  2,233) compared to genotyping data 
(N = 1,021), the status determined by phenotyping was included in 
the analysis.
In InCHIANTI, APOE status was inferred from rs429358 and 
rs7412 SNPs genotyped on Illumina Infinium HumanHap550 chip 
at the Laboratory of Neurogenetics of the U.S. National institute 
on Aging.
In RS, APOE status was assessed at study entry using polymerase 
chain reaction on coded DNA samples.
Assessment of PA
PA was assessed using different questionnaires per cohort which 
are described below. To make the PA measurements comparable be-
tween cohorts, PA was coded in three categories: low, moderate, and 
high PA (reference: low PA) following a similar procedure as de-
scribed by Jonkman and colleagues (23).
In LASA, physical activity was assessed by using the validated 
LASA Physical Activity Questionnaire (LAPAQ) (24), based on the 
questionnaires by Vorrips and colleagues (25) and Caspersen and col-
leagues (26). The frequency and duration of the following activities 
in the previous 2 weeks was assessed: walking, cycling, light house-
hold activities, heavy household activities, and two most frequent 
sports. To take into account the intensity of each activity, metabolic 
equivalent of tasks (MET) was used. The MET-value is based on the 
ratio of work metabolic rate to resting metabolic rate and 1 MET is 
defined as 1 kcal/kg/h. The number of MET-hour for an individual 
spent on a specific activity was calculated by multiplying the MET-
value by time spent on that specific activity (in hours) per week.
In InCHIANTI, PA was assessed using a modified standard 
interview-administered questionnaire (27) in which the participants 
provided data on current PA (28). Participants were asked about the 
frequency and duration of sports and recreational PA. By combining 
the responses and taking into account the intensity of each type of 
activity, participants were classified in one of the three categories:
 (a) inactive, including participants who were completely inactive 
and those who performed low intensity PA.
 (b) light PA, including participants who performed light intensity PA 
for 2–4 hours per week.
 (c) moderate–high PA, including participants who performed at least 
moderate PA >3 hours per week or more and those who per-
formed intense exercise many times per week.
In RS, PA was assessed by an adapted version of the validated 
Zutphen Physical Activity Questionnaire (26). The original ques-
tionnaire contains questions on walking, cycling, gardening, di-
verse sports, and hobbies. To obtain a more complete overview of 
physical activity, questions on housekeeping activities were added. 
Participants were asked how many hours they spent per week on 
these activities during the past 2 weeks. For some activities, like 
sports and gardening, participants were asked whether this activity 
was practiced only during summer or winter. When answered posi-
tive, the given period of time for that activity was divided by two 
(29). MET scores were assigned to each activity and subsequently 
the total MET hours/wk was calculated per each participant.
Journals of Gerontology: MEDICAL SCIENCES, 2020, Vol. 75, No. 10 1881
D
ow
nloaded from
 https://academ
ic.oup.com
/biom
edgerontology/article/75/10/1880/5763509 by Erasm
us U
niversity R
otterdam
 user on 18 N
ovem
ber 2020
Study-specific tertiles were created based on the total MET 
hours/wk in LASA and RS.
Assessment of Cognitive Decline
All three studies assessed cognitive function at each visit using 
MMSE, a 20-item scale ranging from 0 to 30 with higher scores 
indicating better cognitive function (30). A decrease of three or more 
points in MMSE in the following visit was considered as cognitive 
decline. The same definition for cognitive decline has been used in 
other cohort studies (31,32). Furthermore, results from the LEILA 
study, using the reliable change indices method with repeated meas-
urements every 1.5  years, found that a mean MMSE decline of 
three or more points in 3 years is considered a reliable change in 
population-based cohorts of older adults (33).
Assessment of Other Cognitive Tests in LASA
More specific aspects of cognition such as memory and informa-
tion processing that are compromised in dementia were assessed 
in LASA. Episodic memory was assessed using the 15 Words Test, 
the Dutch version of the Auditory Verbal Learning Test (34). The 
test consists of 15 words that have to be learned during 3 trials. 
After every trial the respondent is asked to recall as many words as 
possible. After a distraction period of 20 minutes, the respondent 
is asked to name again the words he learned. The total number of 
words learned during three tests is the recall score (range 0–45). The 
number of words reproduced after 20 minutes is the delayed recall 
score (range 1–15) (22).
Information processing speed was assessed using an adjusted 
version of the Alphabet Coding Task-15 and has been described by 
Piccinin and Rabbit (35). The test was done in three cycles of one mi-
nute and the mean score of the three trials is used in the analysis (22).
These tests were either not available or different from the ones 
used in LASA in the other cohort studies; therefore, the analyses 
were only performed in LASA participants.
Assessment of Covariates
The following covariates were considered: age (years), sex, educa-
tion (less than 9 years of education, 9–12 years of education, more 
than 12 years of education), clinically relevant depressive symptoms 
(Center for Epidemiological Studies Depression Scale ≥16), and 
number of chronic disease (0–1, 2, >2 diseases).
A detailed assessment of covariates is described in the 
Supplementary Material.
Supplementary Table 1 presents an overview of the number of 
participants per wave, methods, and instruments used to assess ex-
posure, outcome, and covariates in each cohort.
Statistical Analysis
The main effect of APOE ɛ 4 and PA and then their interaction ef-
fect (APOE × PA) on cognitive decline were assessed using gener-
alized estimating equations (GEE) with exchangeable correlation 
structure, taking into account repeated measurements. A  binary 
logistic model was used to assess the unadjusted effect estimates. 
In Model 1, we adjusted for sex (dichotomous), age at baseline 
(continuous), and education (categorical, reference category: less 
than 9 years of education). Subsequently, we adjusted for clinic-
ally relevant depressive symptoms (dichotomous) and presence 
of chronic disease (categorical, reference category: 0–1 chronic 
disease) in Model 2.
After running GEE in each study site, the results were meta-
analyzed using random effects to take into account possible het-
erogeneity between studies. The I2 statistic was calculated, which 
measures the percentage of variation between studies that is not due 
to chance: I2 < 25% is considered low heterogeneity. To determine 
whether the heterogeneity was statistically significant, the chi-square 
test of heterogeneity was used (36). For analyses indicating a high 
degree of heterogeneity, we performed three leave-one-out meta-
analyses removing one cohort per time, in order to check the impact 
of potential outlier data on the results.
Sensitivity Analysis
Several sensitivity analyses were performed to test the robustness of 
the results against different aspects of cognitive function and scales of 
PA. First, since the reported levels of PA can be influenced by cognitive 
function, a sensitivity analysis was done including only individuals 
with good cognitive function at baseline (MMSE ≥24). Furthermore, 
to avoid loss of information due to the categorization of PA, a sensi-
tivity analysis was conducted with PA assessed as continuous measure 
(total MET hours/wk divided by standard deviation) for studies in 
which continuous measures were available (ie, LASA and RS). Because 
interaction on the additive scale may reflect biological interaction 
better than interaction on the multiplicative scale (37) the relative ex-
cess risk due to interaction (RERI) was calculated according to the 
procedure proposed by Knol and colleagues (38), with 95% confi-
dence intervals calculated by bootstrapping (N = 1,000).
Extra Analyses in LASA
Analyses assessing different aspects of cognition as memory (total 
recall score, delayed recall score) and information processing speed 
that might be more sensitive than MMSE were done in LASA parti-
cipants. There are no clear cutoffs for what can be considered decline 
in the 15-word test and coding task; therefore, we used as outcome 
the difference in scores between two measurements. Linear regression 
models using GEE with exchangeable correlation structure was fitted.
Analyses in LASA and RS were done using IBM SPSS Statistics 
version 21.0 (IBM Corp, New York) and in InCHIANTI using 
STATA/SE 12.0. RERI was calculated using R (version 3.5.1). The 
meta-analysis of the results was done using the rmeta package and 
bootstrapping was done using boot package in R. The figures were 
made using Review Manager version 5.3.5 a tool from the Cochrane 
Collaboration (39).
Results
A total of 7,176 individuals were included in the main analysis. The 
sample characteristics per study are shown in Table 1 and the base-
line characteristics of the participants without MMSE data at the 
first follow-up are shown in Supplementary Table 2.
Mean age at baseline was higher for InCHIANTI participants 
(72.4 [7.2] years) compared to LASA (69.8 [8.1] years) and RS 
(67.8 [7.4] years). MMSE score at baseline was lower (25.9 [2.7]) 
for InCHIANTI compared to LASA (27.5 [2.1]) and RS participants 
(27.9 [1.7]). Most InCHIANTI participants (88%) had completed 
up to 9 years of education while most LASA and RS participants 
had attained more than 9 years of education. LASA and RS parti-
cipants had a similar percentage of APOE ɛ 4 carriers, respectively 
26.9% and 27.6%, while only 15.2% of the respondents were car-
riers in InCHIANTI (Table 1). Participants who did not have MMSE 
data at the first follow-up were on average older, more often APOE 
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ɛ 4 carriers, and had more often depression or chronic diseases 
(Supplementary Table 2).
The unadjusted effect estimates are presented in Supplementary 
Table 3. In the pooled adjusted analysis, APOE ɛ 4 carriers had higher 
odds of cognitive decline (odds ratio [OR] = 1.46, 95% confidence 
interval [CI]: 1.29, 1.64) compared to noncarriers and the results 
were similar across cohorts (I2 = 19%, p = .29; Figure 1).
Overall, there was no association between PA and cognitive 
decline in the pooled analysis (moderate PA: OR  =  0.87, 95% 
CI: 0.67–1.13; high PA: OR  =  0.71, 95% CI: 0.36–1.40), but 
the heterogeneity between studies was substantial (moderate PA: 
I2 = 78%, p = .01; high PA: I2 = 96%, p < .0001; Figure 2). Similarly, 
there was no association between PA and cognitive decline when 
only LASA and InCHIANTI, LASA, and RS or InCHIANTI and RS 
were meta-analyzed (leave-one-out meta-analysis, Supplementary 
Table 4). In InCHIANTI, higher PA was associated with lower odds 
of cognitive decline (high PA compared to low PA, OR = 0.32, 95% 
CI: 0.23, 0.44), whereas no such associations were seen in LASA 
and RS.
No gene-by-environment interaction between APOE and PA 
in cognitive decline was found in multiplicative scale (APOE × 
moderate PA: OR = 1.03, 95% CI: 0.80–1.33; APOE × high PA: 
OR = 1.02, 95% CI: 0.78–1.32) and there was no heterogeneity be-
tween studies (APOE × moderate PA: I2 = 0.0%, p = .79; APOE × 
high PA: I2 = 0.0%, p = .66; Figure 3).
Moreover, no evidence for interaction on additive scale between 
APOE and PA was found in LASA or InCHIANTI (LASA: moderate 
PA: RERI = −0.11, 95% CI: −0.75, 0.42; high PA: RERI = 0.20, 95% 
CI: −0.37, 0.59; InCHIANTI: moderate PA: RERI = −0.28, 95% CI: 
−1.70, 0.53; high PA: RERI = −0.50, 95% CI: −1.92, 0.28).
Sensitivity Analysis
Analyses including only cognitively healthy individuals at baseline 
(MMSE ≥24) showed similar results (Supplementary Table 5).
Furthermore, also the association of PA and APOE × PA assessed 
using PA in continuous scale in LASA and RS was consistent with the 
main findings (Supplementary Table 6).
Extra Analysis in LASA
In line with the main analyses, APOE ɛ 4 was associated with more 
decline in total recall score, delayed recall score, and information 
processing speed. There was no association of PA with specific 
aspects of cognition and no GxE interaction between APOE and PA 
in total recall score, delayed recall score or information processing 
speed was found (Supplementary Table 7).
Discussion
In this large study conducted among older adults in three prospective 
population-based cohort studies, we aimed to explore whether PA 
might moderate the effect of APOE genotype on cognitive decline. 
The present findings confirmed that APOE ɛ 4 allele was associated 
Figure 1. The association between APOE ɛ 4 and cognitive decline: Results 
from three longitudinal cohort studies. Model 2: Results adjusted for age, 
sex, education, depression, and chronic diseases.
Figure 2. The association between physical activity and cognitive decline: 
Results from three longitudinal cohort studies. Model 2: Results adjusted for 
age, sex, education, depression, and chronic diseases.
Table 1. Baseline Characteristics of the Participants Per Cohort
LASA (N = 1,736) InCHIANTI (N = 843) Rotterdam Study (N = 4,597)
Age at baseline (years), Mean (SD) 69.8 (8.1) 72.4 (7.2) 67.8 (7.4)
Female, N (%) 896 (51.6%) 470 (55.7%) 2,617 (56.9%)
APOE ɛ 4 carriers, N (%) 467 (26.9%) 128 (15.2%) 1,268 (27.6%)
Physical activity Range (MET h/wk) N (%) Range (MET h/wk)
Low 0.2–41.4 122 (14.5%) 2.8–63.4
Moderate 41.5–74.8 383 (45.4%) 63.5–99.3
High 74.9–325.5 338 (40.1%) 99.4–296.3
MMSE at baseline, Mean (SD) 27.5 (2.1) 25.9 (2.7) 27.9 (1.7)
Education, N (%)
Low (<9 y) 685 (39.5%) 742 (88.0%) 505 (11.1%)
Intermediate (9–12 y) 835 (48.2%) 43 (5.1%) 2,025 (44.4%)
High (>12 y) 214 (12.3%) 58 (6.9%) 2,030 (44.5%)
Depression, N (%) 213 (12.3%) 245 (29.1%) 428 (9.4%)
Number of chronic disease, N (%)    
0–1 1,343 (77.4%) 545 (69.3%) 4,080 (88.8%)
2 279 (16.1%) 147 (18.7%) 428 (9.3%)
>2 113 (6.5%) 95 (12.0%) 89 (1.9%)
Note: Low physical activity(PA) corresponds to the inactive category for InCHIANTI and first tertile for LASA and RS; Moderate PA corresponds to the light 
PA category for InCHIANTI and to the second tertile for LASA and RS; High PA corresponds to the moderate–high category for InCHIANTI and the highest 
tertile in LASA and RS.
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with higher risk of cognitive decline. Nevertheless, the GxE inter-
action between APOE genotype and PA was not associated with 
cognitive decline. Thus, the hypothesis that PA might modify the as-
sociation between APOE and cognitive decline was not supported 
by our results.
Our results are in line with the findings from Whitehall II study 
(40), which reported no interaction between APOE ɛ 4 and PA in 
cognitive function in late midlife as well as with the findings from 
UK Biobank (41), which reported no interaction between APOE ɛ 4 
and PA in cognitive abilities in persons aged 40–70 years. However, 
compared to our study, both studies had younger participants and 
did not have longitudinal data on cognitive function. Luck and col-
leagues analyzed data from the German study on Ageing, Cognition 
and Dementia in Primary care Patients (AgeCoDe) and reported 
no GxE interaction in multiplicative scale between APOE ɛ 4 and 
PA in dementia but they found a possible additive interaction in 
Alzheimer’s disease (15). In contrast to our findings, a cohort study 
of 347 older Dutch men found a stronger protective effect of PA in 
cognitive decline in APOE ɛ 4 carriers compared to noncarriers (31). 
The participants in this study were on average older, the follow-up 
period was 3 years compared to 9 years in our study and cognitive 
decline was assessed only once. The different outcome definitions 
used in the literature, the age of the participants, the follow-up time 
and physical activity assessment make it difficult to directly compare 
the results. To date, it can be postulated that the GxE interaction is 
present in AD but there is no evidence of this interaction in cognitive 
decline and cognitive functioning.
Overall, we found no association between PA and cogni-
tive decline; however, the results were heterogeneous between the 
participating cohorts. PA was strongly associated with lower odds 
of cognitive decline in InCHIANTI while in LASA and RS this as-
sociation was not statistically significant. The differences may be 
attributed to different questionnaires used per study or to specific 
population characteristics (ie, older age, lower educational level), 
suggesting that study characteristics should be taken into account 
when comparing results across studies.
Even though the majority of studies in the literature support a 
protective effect of PA in dementia and cognitive decline, the number 
of observational studies reporting no effect has increased in recent 
years. The evidence for a short-term effect (<5 years) is quite robust 
but there seems to be no effect in studies using a longer follow-up. In 
a recent publication from the Whitehall II study PA did not decrease 
the risk of dementia after 28 years follow-up (42). Likewise, when 
examining the association between PA and risk of dementia in RS, 
there was a short-term protective effect of PA using a follow-up up 
to 4 years but no association for longer follow-up (29). Furthermore, 
evidence from clinical trials does not support a long-term protective 
effect of PA on dementia or cognitive decline for follow-up 1 year 
or longer (43).
Strengths of our study include its prospective design, long 
follow-up period, large sample size, and large number of observa-
tions. To the best of our knowledge, this is the first study to analyze 
the GxE interaction between PA and APOE ε 4 in cognitive decline in 
three similar European, population-based, cohort studies. Variations 
in measurement methods were taken into account in the analysis 
plan by creating similar exposure, outcome, and covariate variables 
per study.
Nevertheless, the current study has some limitations. First, PA 
was assessed with self-reported questionnaires, which can be prone 
to information bias. Correlation of LAPAQ questionnaire with ped-
ometer data in LASA was 0.56 (24), whereas the correlation of 
LAPAQ with wrist accelerometer data in RS was 0.3 (44). Second, 
each study assessed PA with different questionnaires, which may 
have contributed to heterogeneity in results. This was taken into 
account by using random effects meta-analysis to pool the data. 
Third, the MMSE is designed as a cognitive screening tool, and 
may not be very sensitive to assess decline in cognitive function. 
However, extra analysis using more specific tests such as 15 Word 
Test and Alphabet Coding Task-15 performed in LASA show similar 
results. Fourth, reverse causality might be present in the association 
between PA and cognitive decline. To account for possible reverse 
causation, a sensitivity analysis including only cognitively healthy 
participants (baseline MMSE ≥24) was performed and the results 
were similar with the main analysis. Fifth, our cohorts included only 
European ancestry participants and generalizability of the results in 
non-European populations should be taken with caution.
Assessment of PA with more objective measurements is needed 
in the future as these may better reflect the total amount of PA. 
Moreover, using a more sensitive test to assess cognitive decline can 
minimize the misclassification of the outcome and detect associ-
ations with more precision.
In spite of previous evidence suggesting a beneficial effect of PA 
in APOE ɛ 4 carriers, we found no evidence for a moderation effect 
by PA in the association between APOE genotype and cognitive de-
cline. Based on our pooled results, PA is not associated with cognitive 
decline in older adults even though there was heterogeneity across 
the three cohorts. Further research is needed to identify subgroups 
where PA can protect against cognitive decline or type of activities 
that are more beneficial for preventing cognitive decline. Meanwhile 
PA in older adults should be encouraged for its protective effects in 
other conditions present at this age group.
In conclusion, the claims of a gene–environment interaction be-
tween APOE ɛ 4 and PA in cognitive decline are not supported by our 
results. There is a need for large sample replications before translating 
results from candidate GxE studies into clinical recommendations.
Supplementary Material
Supplementary data are available at The Journals of Gerontology, 
Series A: Biological Sciences and Medical Sciences online.
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